Cell to Cure ApS: Financial statements 2025
CVR: 39401975
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Cell to Cure ApS (CVR 39401975) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -3,076,475 and a net result of DKK -9,792,604. Equity in the 2025 report amounted to DKK -1,179,103. The company had 12 employees in the financial year.
- Gross Profit
- DKK -3,076,475
- Profit/Loss
- DKK -9,792,604
- Equity
- DKK -1,179,103
- Total Assets
- DKK 9,578,329
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -3.1 mio. | -9.8 mio. | -1.2 mio. | 12 |
| 2023 | - | 100 t. | -1.5 mio. | -1.9 mio. | 5 |
| 2022 | - | 389 t. | -402 t. | -366 t. | 5 |
| 2021 | - | 295 t. | 218 t. | 695 t. | 0 |
| 2020 | - | 523 t. | 405 t. | 462 t. | 0 |
Official annual report
How creditworthy is Cell to Cure ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
On July 7, 2025, the company changed its name from Cell2Cure ApS to Cell to Cure ApS.
Cell to Cure ApS has published its interim report for the period September 1, 2023 – December 31, 2024.
About Cell to Cure ApS
Cell to Cure ApS is a Danish company of the type Anpartsselskab based in Birkerød, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Cell2Cure ApS. The management consists of Jens Kastrup, Annette Ekblond and Mandana Haack-Sørensen. The board consists of Anders Østergaard (chair), Annette Ekblond, Jens Kastrup and Mandana Haack-Sørensen. The company's owners include MEDIC ADVICE ApS, Endeavour Cells ApS and Ekblond.ApS. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -3,076,475 and a net result of DKK -9,792,604. Equity in the 2025 report amounted to DKK -1,179,103.